Endolipid is a biotechnology company focused on developing innovative peptide-based therapies that mimic Sex Hormone-Binding Globulin (SHBG) to address ectopic fat accumulation, particularly in conditions such as Non-Alcoholic Steatohepatitis (NASH) and cellulite. The company operates in the healthcare and pharmaceutical markets, targeting both therapeutic and dermocosmetic applications. Endolipid's business model revolves around research and development, leveraging the extensive expertise of its scientific leaders, Dr. David M. Selva and Dr. Rafael MD, to create proprietary treatments. Revenue is generated through the development and commercialization of these peptide therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical companies. The company serves healthcare providers, dermatologists, and patients seeking advanced treatments for fatty liver diseases and cellulite.

Keywords: SHBG, peptides, NASH, cellulite, ectopic fat, biotechnology, healthcare, dermocosmetic, therapeutic, innovation.